Authors : Bandaru Aashritha; Ambati Akshara; Nandini Kongara; P. Veeresh Babu

Volume/Issue : Volume 10 - 2025, Issue 6 - June

Google Scholar : https://tinyurl.com/msvfna5u

Scribd : https://tinyurl.com/329tvda5

DOI : https://doi.org/10.38124/ijisrt/25jun1371

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Cancer has recently overtaken other conditions as the foremost cause of death worldwide. While numerous conventional treatment modalities and cytotoxic immunotherapies are available, the intricate nature of tumor biology— driven by a multitude of genetic and cellular factors underlying tumorigenesis and metastasis—necessitates the development of advanced treatment approaches capable of acting on cellular as well as genetic fronts. Amid these advancements, Chimeric Antigen Receptor (CAR) T-cell therapy has risen as a pioneering frontier in the domain of T-cell engineering. Here, T cells obtained from the patient are engineered ex vivo to carry synthetic receptors designed to recognize tumor-associated antigens. A key feature is that these modified receptors can identify tumor antigens without requiring MHC presentation. Recently, CAR-T cell therapy has achieved significant clinical milestones, inducing remission in up to 80% of patients with hematologic malignancies, particularly those with acute lymphoblastic leukemia (ALL) and certain subtypes of non-Hodgkin lymphoma, such as large B-cell lymphoma. The anti-CD19 CAR design, UCART19, has demonstrated remarkable therapeutic potency in managing relapsed or refractory hematologic malignancies. Furthermore, other surface antigens, including CD20 and CD22, prevalent in various leukemias and lymphomas, are being actively explored as therapeutic targets, with multiple clinical trials underway. Although its application is presently concentrated on blood cancers, the integration of advanced modalities—such as bispecific CARs, tandem CARs, inhibitory CARs, multi-antigen targeting, CRISPR-based gene editing, and nanoparticle-mediated delivery—holds the promise of significantly enhancing its efficacy. These advancements may extend its utility to both hematologic and solid tumors, offering a treatment paradigm that is not only rapid and precise but also safer compared to traditional modalities. The purpose of this review is to offer an in-depth analysis of the benefits and emerging developments in CAR T-cell immunotherapy, while underscoring its rising advantage over conventional treatments like chemotherapy and radiotherapy.

Keywords : CAR-T Cell Therapy, Cancer Immunotherapy, Hematologic Malignancies, Tumor Antigens, Gene Editing, Targeted Cancer Therapy.

References :

1. Pravin S, Sudhir A. Integration of 3D printing with dosage forms: A new perspective for modern healthcare. Biomed Pharmacother. 2018; 107:146-154.
2. Caterina Rosano, Arfan Ikram M, Mary Ganguli. Neuroepidemiology. 1st ed. Cambridge, United States: Elsevier; 2016.
3. Padmini Bisoyi, A brief tour guide to cancer disease, In: Buddhi Jain, Shweta Pandey, editors. Understanding Cancer. 1st ed. Cambridge, United States: Academic Press; 2022. p. 1-20.
4. White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014; 46(3 Suppl 1): S7-15.
5. Feldman AR, Kessler L, Myers MH, Naughton MD. The prevalence of cancer. Estimates based on the Connecticut Tumor Registry. N Engl J Med. 1986; 315(22): 1394-7.

6. Ali Abdalla YO, Subramaniam B, Nyamathulla S, Shamsuddin N, Arshad NM, Mun KS, Awang K, Nagoor NH. Natural Products for Cancer Therapy: A Review of Their Mechanism of Actions and Toxicity in the Past Decade. J Trop Med. 2022; 2022: 5794350.
7. Harris JA, Ottaviani G, Treister NS, Hanna GJ. An Overview of Clinical Oncology and Impact on Oral Health. Front Oral Health. 2022; 3: 874332.
8. Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, Chen YY, Zhao W. CAR-T design: Elements and their synergistic function. EBioMedicine. 2020; 58: 102931.
9. Ubaid Ahmad, Zafran Khan, Daniya Ualiyeva, Obed Boadi Amissah, Zohaib Noor, Asaf Khan, Nasib Zaman, Marwa Khan, Ayub Khan, Babar Ali. Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. Advances in Cancer Biology - Metastasis 2022; 4: 100035.
10. Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: A new era for cancer treatment (Review). Oncol Rep. 2019; 42(6): 2183-2195.
11. Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023; 14: 1188049.
12. Sun W, Jiang Z, Jiang W, Yang R. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence. Cancer Treat Res Commun. 2022; 33: 100638.
13. Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017; 168(4): 724-740.

14. Liyanran Yan, Shanzi Gao, Xinhui Wang, Xintao Zhou, Praopim Limsakul, Yiqian Wu. Boosting CAR-T cell therapy with CRISPR technology. hLife 2024; 2(8): 380-396.
15. Anuvab Dey, Subhrojyoti Ghosh, Shreya Jha, Subhranil Hazra, Nainika Srivastava, Urmimala Chakraborty, Anupriya Guha Roy. Recent advancement in breast cancer treatment using CAR T cell therapy: - A review. Advances in Cancer Biology - Metastasis 2023; 7: 100090.
16. Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018; 8(4): 539-551.
17. Ligon JA, Fry A, Maher JY, Foley T, Silbert S, Yates B, Gomez-Lobo V, Wiener L, Shah NN. Fertility and CAR T-cells: Current practice and future directions. Transplant Cell Ther. 2022; 28(9): 605.e1-605.e8.
18. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM. Axicabtageneciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine. 2017; 377(26): 2531-44.
19. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England journal of medicine. 2020; 382(14): 1331-42.
20. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. The Lancet. 2021; 398(10299): 491-502.
21. Munshi NC, Anderson Jr LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P. Idecabtagenevicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine. 2021; 384(8): 705-16.
22. Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal for immunotherapy of cancer. 2020; 8(2): e001511.
23. Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, Laetsch TW, Wiener L, Gardner RA, Nussenblatt V, Hill JA. Beyond the storm—subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology. 2021; 18(6): 363-78.
24. Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, Sorror ML, Turtle CJ, Maloney DG, Bar M. Late events after treatment with CD19- targeted chimeric antigen receptor modified T cells. Biology of Blood and Marrow Transplantation. 2020; 26(1): 26-33.
25. Chow EJ, Kamineni A, Daling JR, Fraser A, Wiggins CL, Mineau GP, Hamre MR, Severson RK, Drews-Botsch C, Mueller BA. Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis. Archives of pediatrics & adolescent medicine. 2009; 163(10): 887-94.
26. Gnaneswaran S, Deans R, Cohn RJ. Reproductive late effects in female survivors of childhood cancer. Obstetrics and gynecology international. 2012; 2012(1): 564794.
27. Hudson MM. Reproductive outcomes for survivors of childhood cancer. Obstetrics & Gynecology. 2010; 116(5): 1171-83.
28. Patel V, Jones P, Judd A, Senko V, Altieri G, Pettee D. Recollection of fertility discussion in adolescent and young adult oncology patients: a single-institution study. Journal of Adolescent and Young Adult Oncology. 2020; 9(1): 72-7.
29. Benedict C, Thom B, Friedman DN, Pottenger E, Raghunathan N, Kelvin JF. Fertility information needs and concerns post-treatment contribute to lowered quality of life among young adult female cancer survivors. Supportive care in cancer. 2018; 26: 2209-15.
30. Rossi G, Kicinski M, Suciu S, Vandecruys E, Plat G, Uyttebroeck A, Paillard C, Barbati M, Dresse MF, Simon P, Minckes O. Fertility status among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: results of the 58 Late Adverse Effects study. Human Reproduction. 2022; 37(1): 44-53.
31. Close AG, Dreyzin A, Miller KD, Seynnaeve BK, Rapkin LB. Adolescent and young adult oncology—past, present, and future. CA: a cancer journal for clinicians. 2019; 69(6): 485-96.
32. van Der Meer DJ, Karim-Kos HE, van Der Mark M, Aben KK, Bijlsma RM, Rijneveld AW, van Der Graaf WT, Husson O. Incidence, survival, and mortality trends of cancers diagnosed in adolescents and young adults (15–39 years): a population-based study in The Netherlands 1990–2016. Cancers. 2020; 12(11): 3421.
33. Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertility and Sterility. 2019; 112(6): 1022-33.
34. Meacham LR, Burns K, Orwig KE, Levine J. Standardizing risk assessment for treatment-related gonadal insufficiency and infertility in childhood adolescent and young adult cancer: the pediatric initiative network risk stratification system. Journal of adolescent and young adult oncology. 2020; 9(6): 662-6.
35. Green DM, Liu W, Kutteh WH, Ke RW, Shelton KC, Sklar CA, Chemaitilly W, Pui CH, Klosky JL, Spunt SL, Metzger ML. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. The Lancet Oncology. 2014; 15(11): 1215-23.
36. Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022; 602(7897): 503-9.
37. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, Donaldson SS, Byrne J, Robison LL. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. Journal of Clinical Oncology. 2009; 27(16): 2677-85.
38. Callahan C. Pediatric survivorship: considerations following CAR T-cell therapy. Number 2/April 2019. 2019; 23(2): 35-41.
39. Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. Journal of Clinical Oncology. 2022; 40(9): 945-55.
40. Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. Journal of Clinical Oncology. 2022; 40(9): 932-44.
41. Cosgrove C, Dellacecca ER, Van Den Berg JH, Haanen JB, Nishimura MI, Le Poole IC, Bergmans HE. Transgenerational transfer of gene-modified T cells. Journal for immunotherapy of cancer. 2019; 7: 1-4.
42. Zver T, Frontczak S, Poirot C, Rives-Feraille A, Leroy-Martin B, Koscinski I, Arbez-Gindre F, Garnache-Ottou F, Roux C, Amiot C. Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients. Journal of Ovarian Research. 2022; 15(1): 9.
43. Holland EM, Yates B, Ling A, Yuan CM, Wang HW, Stetler-Stevenson M, LaLoggia M, Molina JC, Lichtenstein DA, Lee DW, Ligon JA. Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. Blood advances. 2022; 6(7): 2167-82.